8-KItem 1.01 · Material AgreementItem 2.03 · Financial ObligationItem 2.06 · Material ImpairmentsItem 9.01 · Financial Statements
Molina to record an estimated $93M non‑cash, pre‑tax impairment in Q1 2026 tied to certain intangible…
Filed with the SEC on · Summarized by InvestorsBot
Molina to record an estimated $93M non‑cash, pre‑tax impairment in Q1 2026 tied to certain intangible assets; decision made Feb 5, 2026. $MOH ⚠️ #MolinaHealthcare #SECfiling
Impairment stems from Molina’s exit of its Medicare Advantage Prescription Drug product for 2027 as it pivots to focus exclusively on dual‑eligible Medicare members. Charge recorded outside “adjusted net income.” $MOH 📌 #Medicare #Strategy
Investors: the ~$93M is non‑cash and will hit GAAP pre‑tax results in Q1 2026 but is excluded from adjusted net income per Molina’s Feb 5, 2026 earnings release (see Form 8‑K). $MOH 💡 #Investing #Healthcare